MoonLake Immunotherapeutics (MLTX) Total Non-Current Liabilities (2021 - 2026)

MoonLake Immunotherapeutics' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $100.2 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 34.18% year-over-year to $100.2 million; the TTM figure through Mar 2026 stood at $100.2 million (up 34.18% YoY), while the FY2025 annual figure was $74.5 million, up 3482.2% from the prior year.
• Total Non-Current Liabilities was $100.2 million for Q1 2026 at MoonLake Immunotherapeutics, up from $74.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $100.2 million in Q1 2026 to a low of $4985.0 in Q3 2022.
• Historically, Total Non-Current Liabilities has averaged $25.9 million across 5 years, with a median of $2.6 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities jumped 5285.82% in 2023, then plunged 32.57% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $411157.0 in 2022, then surged by 649.94% to $3.1 million in 2023, then tumbled by 32.57% to $2.1 million in 2024, then jumped by 3482.2% to $74.5 million in 2025, then surged by 34.59% to $100.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $100.2 million (Q1 2026), $74.5 million (Q4 2025), and $74.8 million (Q3 2025), per Business Quant data.